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Abstract
Background: Intraoperative haemorrhage is a known predictor for perioperative outcome of patients
undergoing hepatic resection. While anaesthesiological lowering of central venous pressure (CVP) by fluid
restriction is known to reduce bleeding during transection of the hepatic parenchyma its potential side
effects remain poorly investigated. In theory it may have negative effects on kidney function and tissue
perfusion and bears the risk to result in severe haemodynamic instability in case of profound intraoperative
blood loss. The present randomised controlled trial evaluates efficacy and safety of infrahepatic inferior
vena cava (IVC) clamping as an alternative surgical technique to reduce CVP during hepatic resection.
Methods/Design: The proposed IVC CLAMP trial is a single-centre randomised controlled trial with a
two-group parallel design. Patients and outcome-assessors are blinded for the treatment intervention.
Patients undergoing elective hepatic resection due to any reason are enrolled in IVC CLAMP. All patients
admitted to the Department of General-, Visceral-, and Transplant Surgery, University of Heidelberg for
elective hepatic resection are consecutively screened for eligibility and written informed consent is
obtained on the day before surgery. The primary objective of this trial is to assess and compare the amount
of blood loss during hepatic resection in patients receiving surgical CVP reduction by clamping of the IVC
as compared to anaesthesiological CVP without infrahepatic IVC clamping reduction. In addition to blood
loss a set of general as well as surgical variables are analysed.
Discussion:  This is a randomised controlled patient and observer blinded two-group parallel trial
designed to assess efficacy and safety of infrahepatic IVC clamping during elective hepatectomy.
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Background
The outcome of patients undergoing hepatic resection has
markedly improved since the late 1980's [1]. High-vol-
ume centres currently report morbidity and mortality
rates of 30 - 45% and 3 - 4% [1-3], respectively and
hepatic resections can nowadays be safely carried out
without routine use of portal triad clamping with its
potential drawback of ischaemia and reperfusion injury
[4]. The decrease of intraoperative blood loss and need for
blood transfusion, two well-known predictors for the out-
come of patients undergoing hepatic resection [3,5], are
considered main contributors for the decrease in morbid-
ity and mortality. The observed lower blood loss and
transfusion rates most likely result from advances in peri-
operative care and in particular the reduction of central
venous pressure (CVP) during transection of the liver
parenchyma. Several non-randomised as well as one ran-
domised trial reported reduction of CVP to result in signif-
icantly less intraoperative blood loss [6-8]. For this reason
many surgeons currently prefer to perform hepatic resec-
tions after previous CVP reduction below 5 mmHg which
is usually achieved by restricted intravenous fluid admin-
istration, and - if required - the application of diuretics
and nitroglycerine [8]. This approach is effective in lower-
ing CVP and by this intraoperative bleeding. However, it
bears the risk of various side effects and data on its safety
are scarce. Besides impairment of kidney function and tis-
sue oxygenation, hypovolaemic patients are at risk for
haemodynamic instability particularly in case of unex-
pected intraoperative haemorrhage. Moreover, systemic
response to restricted volume administration is mostly
unknown and requires further research. Based on these
potential drawbacks the optimal strategy for the reduction
of bleeding during hepatectomy remains a matter of
debate.
Selective clamping of the inferior vena cava (IVC) below
the liver might serve as an alternative technique to reduce
CVP during transection of the liver parenchyma. This
approach allows the surgeon to operate under the condi-
tion of lowered CVP without the requirement of systemic
fluid restriction. The current trial is designed to assess effi-
cacy and safety of selective infrahepatic IVC clamping
without previous anaesthesiological CVP reduction as
compared to current standard of CVP reduction via fluid
restriction and administration of diuretics or nitro-com-
pounds without clamping of the IVC.
Existing evidence and need for the trial
To assess available evidence, we conducted a systematic
literature search of the Medline database according to the
criteria of the Cochrane Collaboration (search date: Sep-
tember 4th 2008). Furthermore, the reference lists of rele-
vant articles on hepatic vascular control were cross-
searched manually for additional studies. The search
found several randomised trials evaluating various clamp-
ing techniques for reduction of bleeding during hepatec-
tomy [9-13]. Otsubo et al. provided the first report of
infrahepatic IVC clamping in a retrospective study of 103
consecutive patients with CVP > 5 mmHg who underwent
right or left hemihepatectomy [14]. While this study
revealed reduced bleeding for those patients who received
IVC clamping below the liver and suggested a positive
impact of IVC clamping on bleeding and potentially out-
come of patients undergoing hepatectomy, it's retrospec-
tive, non-randomised study design does not allow for
general recommendation of infrahepatic IVC clamping.
Kato et al. published a randomised controlled trial (RCT)
evaluating IVC clamping in combination with anaesthesi-
ological CVP reduction in patients undergoing liver resec-
tion [15]. The overall design of this trial comparing
anaesthesiological CVP reduction to anaesthesiological
CVP reduction with additional infrahepatic IVC clamping
does not allow for conclusions regarding the treatment
effect of infrahepatic IVC clamping in euvolaemic
patients. To our knowledge there is currently no RCT
available comparing the anaesthesiological CVP reduc-
tion (by fluid restriction, use of diuretics, nitro-com-
pounds with no clamping of the IVC) to the surgical CVP
reduction (by transient clamping of the IVC below the
liver without fluid restriction).
Aim of this trial
Reduction of blood loss is a major goal in hepatic resec-
tions, as major blood loss is a known predictor of patient's
outcome [3,5]. Unfortunately, most surgical techniques
which aim to decrease bleeding during hepatectomy
include portal triad clamping bearing the risk of ischae-
mic/reperfusion injury to the liver remnant. Reduction of
CVP as currently performed may have detrimental effects
on tissue perfusion and kidney function and may, moreo-
ver, result in severe haemodynamic instability in case of
intraoperative haemorrhage. For this reason the present
randomised trial evaluates the technique of selective inf-
rahepatic IVC clamping to lower CVP in patients undergo-
ing hepatectomy without routine use of portal triad
clamping and without concomitant anaesthesiological
CVP reduction. Patients in the control group are treated
according to the current local standards consisting of
anaesthesiological CVP reduction primarily achieved via
fluid restriction and application of diuretics or nitro-com-
pounds without routine use of any kind of vascular
clamping.
Methods/design
Trial population and patient recruitment
Patients scheduled for elective hepatic resection due to
any reason may be enrolled in IVC CLAMP. Table 1 dis-
plays the detailed inclusion and exclusion criteria. All
patients admitted to the Department of General, VisceralTrials 2009, 10:94 http://www.trialsjournal.com/content/10/1/94
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and Transplant Surgery, University of Heidelberg are con-
secutively screened for eligibility and written informed
consent is obtained on the day before surgery.
Safety aspects
All hepatectomies within IVC CLAMP are carried out by
experienced hepatic surgeons. A recently published article
on 300 hepatectomies performed at the Department of
General, Visceral and Transplant Surgery, University of
Heidelberg using anaesthesiological CVP reduction dem-
onstrated hepatic resections of being safe without routine
use of inflow control [2]. Hence, patients randomised to
the control group face no additional risk as compared to
patients treated at the department outside of the trial.
Infrahepatic IVC clamping lowers the CVP potentially
without systemic effects of hypovolemia such as microcir-
culatory disturbances. It might therefore protect the
patient from these unwanted sequelae of hypovolaemia
and may improve patient's outcome. Haemodynamic
intolerance is, however, a potential side effect of this inter-
vention. For this reason each patient's medical history is
scrutinised for the presence of medical conditions putting
the individual patient at increased risk of not tolerating
the procedure. Patients with severe heart disease, namely
severe coronary artery disease (CAD) requiring interven-
tion or cardiac insufficiency (New York Heart Association,
NYHA IV [16]) are excluded from the study. To assess
patients' hemodynamic tolerance the IVC is clamped for a
short test period prior to the actual parenchymal transec-
tion. Moreover, patients are monitored very closely by the
anaesthetist and the surgeon immediately stops IVC
clamping in case it is not tolerated by the individual
patient.
For the assessment of safety, adverse events (AE) and seri-
ous adverse events (SAE) are documented on separate
forms and analysed within the safety analysis. Besides
SAEs a set of predefined AEs is documented within IVC
CLAMP (Table 2).
The principal investigator may terminate the trial at any
time in consultation with the key research associates and
the biostatistician. Reasons for termination include inci-
dence or severity of AEs indicating a potential health haz-
ard caused by either study treatment and external
evidence indicating likewise or requiring premature termi-
nation of the trial.
Standardisation of treatments
Standardisation of anaesthesiological care
All patients are treated according to local standards of the
Department of Anaesthesiology, University of Heidelberg:
Preoperative Care
Patients are asked to stop eating and drinking from mid-
night before surgery. Fluid loss due to fasting is not
replaced before induction of anaesthesia.
Approximately 30 minutes before induction of anaesthe-
sia sedation medication (Midazolam 3.5-7.5 mg) is
administered adapted to body weight and individual
demand at executing anaesthetist's discretion.
Table 1: Eligibility criteria for IVC CLAMP.
Inclusion criteria Exclusion criteria
• Age ≥ 18 years ￿ Presence of medical conditions putting the individual patient at increased risk 
for not tolerating liver resection:
￿ Elective hepatic resection due to any reason - Liver cirrhosis (Child-Pugh B or C)
￿ American Society of Anaesthesiologists (ASA) score I to III [26] - (Hereditary) coagulopathy
￿ Written informed consent ￿ Presence of medical conditions putting the individual patient at increased risk 
of not tolerating at least one of this trial's study interventions:
- Severe heart disease (e.g. severe coronary artery disease requiring 
intervention, cardiac insufficiency NYHA stage IV) [16]
- Pulmonary hypertension
- Renal insufficiency (serum creatinine > 2 mg/dl or > 177 μmol/l; conversion 
factor 88.4 or requiring dialysis)
- Uncorrected electrolyte imbalance
￿ Atrial fibrillation
￿ For female patients: pregnancy or lactation
￿ Technical impossibility of hepatic resection
￿ Participation in other clinical trials or observation period of competing trials 
interfering with the endpoints of this trial
￿ Former participation in the clinical trial
￿ Suspected lack of compliance
￿ Impaired mental state or language problemsTrials 2009, 10:94 http://www.trialsjournal.com/content/10/1/94
Page 4 of 11
(page number not for citation purposes)
Immediate Preoperative Care
Once entered operating theatre patients are equipped with
a 18 or 20 gauge peripheral venous catheter. Patients are
treated with either combined neuraxial and general anaes-
thesia or general anaesthesia only. Decision for or against
neuraxial anaesthesia is based on executing anaesthesiol-
ogist's clinical judgement and on patients' choice, i.e.
written informed consent.
Neuraxial anaesthesia, i.e. thoracic epidural catheter is
tested using Lidocain (60-80 mg). Analgesia is induced
using Sufentanil (20 μg) and Ropivacain (40-50 mg).
Over the last 30 minutes before testing and induction of
analgesia up to 10 ml/kg body weight of any crystalloid
fluid preparation are administered to replace relative
blood loss (internal blood loss due to loss of vascular
tone). Analgesia in maintained using Ropivacain (40-50
mg/h), again.
Table 2: Secondary endpoints of the IVC CLAMP Trial.
Secondary endpoint Definition and assessment of outcomes
Blood transfusions: Administration of PRBC transfusion is documented for the intraoperative and postoperative 
period until 48 hours postoperatively. Documentation includes number of patients receiving 
PRBC transfusions as well as amount of transfused packed red blood cells [ml]. Transfusion 
triggers are given in table 4 to standardize administration of PRBC.
Operation time [min]: Time from skin incision to placement of last skin staple/suture.
Transection time [min]: Time from beginning to end of liver transection.
Transection area [cm2]: Surface area of the specimen.
Duration of postoperative hospital stay [days]: Time from day of operation to day of discharge.
Duration of ICU stay [days]: Time on the Intensive Care Unit (ICU). Patients' stay in the recovery room and Intermediate 
Care (IMC) unit exceeding 24 hours is considered as ICU stay.
Morbidaity: Besides SAEs the following predefined complications are documented as AEs within IVC 
CLAMP:
Posthepatectomy haemorrhage: Drop of haemoglobin >3 g/dl (after 6 hours after the end of 
surgery) or any postoperative transfusion of PRBCs for a falling haemoglobin and/or the need for 
reintervention (i.e. embolisation or re-laparotomy)
Postoperative biliary leakage: Presence of bile fluid (bilirubin level > twice the serum level) in the 
abdominal cavity or drains > 48 hours beyond the end of surgery or the need for reintervention 
(i.e. interventional drainage or relaparotomy due to bile fluid collections or biliary peritonitis).
Further biliary complications: Biliary complications such as postoperative biliary stricture detected 
via ERCP or MRCP
Intraabdominal fluid collection/abscess: Intraabdominal fluid collection detected on any imaging 
modality (e.g. ultrasound, CT scan) associated with abdominal discomfort/pain or elevation of 
infectious parameters.
Posthepatectomy liver failure: Postoperative deterioration of the liver's synthetic, excretory, and 
detoxifying functions ≥ day 5:
￿ Increased INR or need of coagulation products (FFP, coagulation factors) to normalize the 
INR
￿ Serum bilirubin ≥ twice upper limit of normal
￿ Encephalopathy
- Pneumonia: Pulmonary infection with evidence of increased infection parameters (CRP > 2 mg/
dl and/or leukocytes > 10 000/ml) which are unlikely to be caused by a different pathologic 
process and evidence of pulmonary infiltrates on chest x-ray, requiring antibiotic therapy.
In-hospital mortality: Death due to any reason within the patient's initial hospital stay.
Liver function: ALT, AST, GGT, Quick's time/INR, bilirubin, and albumin preoperatively, intraoperatively and 
on postoperative days 1, 3 and 7.
Kidney function: Serum creatinine and BUN preoperatively, intraoperatively and on postoperative days 1, 3 and 
7.
Need for portal triad clamping: Need for additional vascular control during actual parenchymal transection.
Haemodynamics and haemodynamic intolerance: Heart rate, blood pressure and CVP are documented during liver transection. If fluid 
administration plus additional PRBCs prove insufficient in maintaining mean arterial pressure of 
at least 65 mmHg as does the use of up to 0.2 μg/kg body weight Noradrenaline every minute in 
infusion injection (i.e. 40 ml/h of Noradrenaline 1 mg/50 ml in a 70 kg body weight standard 
patient), executing anaesthetist may use up to two times 100 μg of Noradrenaline in bolus 
injections. If the executing anaesthetist uses Noradrenaline in bolus injections the patient is not 
considered haemodynamically stable any more. If the executing anaesthetist uses more than two 
times 100 μg of Noradrenaline in bolus injections the patient is considered in a life-threatening 
condition and treatment according to protocol is terminated. In this case the patient is analysed 
according to intention-to-treat.
Re-laparotomy: Laparotomy within 30 days after the index operation.Trials 2009, 10:94 http://www.trialsjournal.com/content/10/1/94
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General anaesthesia is induced using either Thiopental (3-
5 mg/kg body weight) or Propofol (1-2 mg/kg body
weight) with additional Fentanyl (2-4 μg/kg body weight)
or Sufentanil (0.2-0.4 mg/kg body weight) and Atracu-
rium (0.5-0.6 mg/kg body weight), Cisatracurium (0.15
mg/kg body weight) or Rocuronium (0.6 mg/kg body
weight). Anaesthesia is maintained using either Sevoflu-
ran (minimum alveolar concentration 0.8) or Desfluran
(minimum alveolar concentration 0.8) with additional
Fentanyl (up to 10 μg/kg body weight total) or Sufentanil
(up to 1 μg/kg body weight total), again.
All drugs are administered adapted to body weight and
individual demand within ranges given, in case of Ropi-
vacain adapted to height and individual demand.
Immediately after successful induction of anaesthesia
each patient is being equipped with:
￿ Gastric tube
￿ 20 gauge arterial catheter
￿ 14 gauge peripheral venous catheter
￿ Twin lumen central venous catheter
￿ In case of prior abdominal surgery transurethral
catheter (in other cases a suprapubic catheter is placed
intraoperatively)
Intraoperative care
Patients are randomised to either surgical or anaesthesio-
logical intervention once entering the operation theatre
using consecutively numbered, opaque and sealed enve-
lopes. Surgical intervention consists of standard intrave-
nous fluid therapy according to local standards based on
current textbook opinion (Table 3) [17] and infrahepatic
IVC clamping for the transection period. Anaesthesiologi-
cal intervention consists of goal-directed intravenous fluid
therapy according to local standards. Effect variable for
goal-directed fluid therapy is CVP of no more than 5
mmHg. If goal of therapy cannot be attained using
restricted intravenous fluid therapy only, further means
necessary may be taken, namely administration of opioids
within given ranges, administration of nitro compounds,
or administration of diuretics at discretion of executing
anaesthetist. Minimum requirement for intravenous fluid
therapy is the administration of at least 1 ml/kg body
weight + 40 ml of any crystalloid fluid preparation every
hour, the algorithm for the administration of packed red
blood cells (PRBC) is displayed in table 4.
If fluid administration plus additional RPBC prove insuf-
ficient in maintaining mean arterial pressure of at least 65
mmHg, the executing anaesthetist may use up to 2 ml of
Akrinor® (up to 200 mg Cafedrin/10 mg Theodrenalin) in
bolus injections. In addition the executing anaesthetist
may use up to 0.2 μg/kg body weight Norepinephrin every
minute in infusion injection (i.e. 40 ml/h of Noradrena-
line 1 mg/50 ml in a 70 kg body weight standard patient)
and up to two times 100 μg Norepinephrin in bolus injec-
tions. If Noradrenaline is used in bolus injections the
patient is not considered haemodynamically stable any
more. The need for more than two times 100 μg
Noradrenaline in bolus injections defines a life-threaten-
ing condition and treatment according to protocol is ter-
minated (in this case the patient is analysed according to
intention-to-treat).
Standardisation of surgical technique
Patients receive single shots of mezlocilline (4 g) and met-
ronidazole (0.5 g) 30 minutes prior to incision. After
being placed in supine position, patients are prepared and
draped in a sterile fashion. Following a roof-top incision
(with or without extension in the midline to the xiphoid),
a reversed L-shaped incision from the xiphoid to the tip of
the twelfth right rib, or a standard transverse abdominal
incision, the abdomen is initially explored for extrahe-
patic disease. The falciform triangular ligament is mobi-
lised and dissected to expose the hepatic veins and porta
hepatis. To fully mobilise the liver, short hepatic and cau-
date veins from the IVC are clipped or ligated.
In general, transection of the liver parenchyma within IVC
CLAMP is recommended to be performed as stapler hepa-
Table 3: Fluid management according to current textbook opinion [17].
Compensatory 
intravascular 
volume expansion 
(with epidural 
anaesthesia) [mL]
Compensatory 
intravascular 
volume expansion 
(without epidural 
anaestesia) [mL]
Deficit [mL/h] Maintenance 
[mL/h]
Third space [mL/h] Blood loss [mL]
CrF: Body weight [kg] 
× 10 [mL/kg]
CrF: Body weight [kg] 
× 5-7 [mL/kg]
CrF: (Body weight + 
40) [kg] × [mL/kg/h]
CrF: (Body weight + 
40) [kg] × [mL/kg/h]
CrF: Body weight [kg] 
× 4-6 [mL/kg/h]
CrF: 3:1 
[volume:volume]
CoF: 1:1 
[volume:volume]
mL = mililiters; h = hours; kg = kilogramms; CrF = Crystalloid solutions; CoF = Colloidal solutionsTrials 2009, 10:94 http://www.trialsjournal.com/content/10/1/94
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tectomy to further standardise liver resection. However,
should stapler hepatectomy not be feasible or considered
to be potentially harmful to the patient, the ultrasonic dis-
section or the clamp-crushing technique may be chosen
by the executing surgeon. The transection technique is
documented and considered as a factor in covariance
analysis and the interaction with intervention will be
tested. While routine use of portal triad clamping is not
recommended, the final choice to use portal is left at dis-
cretion of the executing surgeon and the need for portal
triad clamping is documented as a secondary endpoint.
Argon beam coagulation is applied to stop minor oozing
once resection is completed and sealants may be used, if
deemed necessary by the executing surgeon. After hae-
mostasis is considered secure, easy-flow drains are placed
in the subphrenic and subhepatic space and the abdomen
is closed in a standardised manner.
Trial interventions
Group A: Inferior vena cava clamping during hepatic resection
After laparotomy, the IVC is dissected free below the liver.
Prior to the beginning of the actual transection period the
IVC is briefly clamped with a vascular clamp to assess
haemodynamic tolerance. In case the patient tolerates IVC
clamping, transection of the parenchyma is started.
Patients in this study group receive intravenous volume
for maintenance of fluid homoeostasis according to local
standard and current textbook opinion, i.e. intravenous
fluid therapy sufficient to maintain normovolaemia
judged by standard vital signs with special emphasis on
CVP of 5-12 mmHg.
Group B: No clamping during hepatic resection
Patients in this study group undergo hepatic resection
according to local standards of the Departments of Gen-
eral-, Visceral- and Transplant Surgery and the Depart-
ment of Anaesthesiology, University of Heidelberg.
Current practice requires CVP reduction by goal-directed
intravenous fluid therapy, diuretics, and nitro compounds
without any routine use of hepatic vascular control. Effect
variable for goal-directed fluid therapy is CVP of no more
than 5 mmHg. Furthermore, additional i.v. fentanyl, rop-
ivacain via the epidural catheter and positive end-expira-
tory pressure (PEEP) to zero may be used to lower CVP
below 5 mmHg.
Study objectives and endpoints
It is the primary objective of this trial to assess and com-
pare the amount of blood lost during hepatic resection in
patients receiving surgical CVP reduction as compared to
anaesthesiological CVP reduction without infrahepatic
IVC clamping. In addition to blood loss a set of general as
well as surgical variables are assessed.
Intraoperative blood loss [ml], i.e. the blood lost from
skin incision until skin closure, was chosen as the primary
endpoint. The amount of blood lost is measured from the
amount of blood collected in the suction containers
including blood squeezed from sponges and gauzes. The
irrigation volume is subtracted. An independent study
nurse documents intraoperative blood loss. Furthermore,
an independent study nurse blinded to the allocated inter-
vention documents all other endpoints.
Secondary endpoints are chosen in accordance with
recently published randomised trials in the field of
hepatic surgery [18-20]. The secondary endpoints are pre-
sented in Table 2.
Trial implementation
Visits within IVC CLAMP are carried out by a study nurse
blinded to the allocated treatment. Study visits and
Table 4: Transfusion triggers during the IVC CLAMP Trial.
Risk profile Minimum hemoglobin (conversion factor 0.621)
< 40 years
no additional risk factors
no organ function impairment
<5.5 g/dl or 3.4 mmol/l
≥ 40 years
no additional risk factors
no organ function impairment
<6 g/dl or 3.7 mmol/l
organ function impairment <7 g/dl or 4.3 mmol/l
coronary artery disease with no ischemia
carotid artery stenosis with no ischemia
history of transient ischemic attack
<8 g/dl or 5.0 mmol/l
coronary artery disease with ischemia e.g. troponin elevation
carotid artery stenosis with ischemia
history of stroke
<10 g/dl or 6.2 mmol/lTrials 2009, 10:94 http://www.trialsjournal.com/content/10/1/94
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acquired data within IVC CLAMP are displayed in Table 5.
The laboratory tests within IVC CLAMP are summarised in
Table 6.
Sample size
The sample size is based on the primary efficacy endpoint
variable and the primary analysis. Assuming a pooled
standard deviation in blood loss of 458 ml (calculated
from data taken from the literature [2,14] and internal
observations at the Department of General, Visceral and
Transplant Surgery, University of Heidelberg), 48 patients
per group are needed to detect a difference of 280 ml with
a significance α = 5% and a power of (1 - β) = 80% using
two-sided t-test.
Taking into account the possible loss of power by using
one additional factor in the analysis of covariance,
another 8 patients per treatment group are randomised.
The continuous covariates applied in this analysis do not
decrease the power and therefore are not included in the
sample size estimation.
As randomisation is carried out before laparotomy an
intraoperative drop-out rate of 30% is assumed to con-
sider possible intraoperative findings preventing hepatic
resection (e.g. extrahepatic disease such as peritoneal car-
cinomatosis, technically inoperable disease, severe liver
cirrhosis etc). Thus the total sample size accounts for 152
patients.
Statistical analysis
Statistical methods are used to assess the quality of data,
homogeneity of treatment groups, endpoints and safety of
the two intervention groups. The confirmatory analysis is
performed based on the intention-to-treat (ITT) patients
and with respect to ITT principles.
Categorical data are summarised by means of absolute
and relative frequencies (count and percent). Continuous
data are presented by the following summary statistics:
the number of observations, arithmetic mean, standard
deviation, minimum, median and maximum. Wherever
appropriate, results of these analyses are visualised (box-
whisker plots or histograms).
The primary efficacy endpoint is intraoperative blood loss
measured as previously described. The underlying two
sided null-hypothesis is that both interventions lead to
similar means in intraoperative blood loss:
The alternative hypothesis is that one intervention per-
forms better than the other:
A confirmatory intention to treat analysis (2-sided test),
including all patients as randomised, is calculated for the
H0 12 0 : mm −=
H1 12 0 : mm −≠
Table 5: Flow chart of the IVC CLAMP-Trial.
Screening Intervention Follow up
Visit 1
(up to 30 days before surgery)
Visit 2
(day of surgery)
Visit 3
(POD 1)
Visit 4
(POD 3)
Visit 5
(POD 7 or day of discharge)
Selection criteria
Informed consent
X
Medical history
Demographics
X
Physical examination X
Laboratory tests1 XX X X
Intraoperative outcomes X
Postoperative outcomes X
1For detailed description of laboratory test done see table 6. POD, Postoperative day
Past/current medical history: past/current medical/surgical history i.e. concomitant/underlying illness (indication for surgery)
Demographics: age [years], sex, ASA-class [26], NYHA-class [16]
Physical examination: height [m], body weight [kg], smoking habits [packs/day, pack years]
Intraoperative outcome measures: intraoperative blood loss, intraoperative PRBC transfusion, haemodynamics/haemodynamic instability, operation 
time, transection time, transection area, use of portal triad clamping, performed resection type/extent, transection technique, and mortality
Postoperative outcome measures: postoperative RPBC transfusion (until 48 h), postoperative complications/morbidity, duration of hospital stay, 
duration of ICU stay, mortalityTrials 2009, 10:94 http://www.trialsjournal.com/content/10/1/94
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mean intraoperative blood loss between the two groups.
Analysis of covariance techniques are used to detect possi-
ble treatment differences, with transection technique as
additional factor and International Normalized Ratio
(INR) as coagulation measure, the actual resection surface
area and CVP during transection as continuous covariates.
Secondary endpoints are analysed in an exploratory way,
using appropriate statistical methods based on the under-
lying distribution of the data. Sensitivity analyses are cal-
culated including different patient populations (per-
protocol patients) and different statistical methods (t-
test). All analyses are done using the SAS™ program Ver-
sion 9.1.
Randomisation and methods to minimise bias
Patients are randomly allocated to either study interven-
tion to balance treatment groups for all known and
unknown potentially confounding factors. The Institute
for Medical Biometrics and Informatics (IMBI) generates
a block randomisation list using SAS (SAS™ Version 9.1.,
SAS Institute Inc., Cary, USA). To reduce costs, patients are
randomised using consecutively numbered opaque enve-
lopes prepared and sealed by an independent study nurse.
All patients screened as well as those included and ran-
domised in the study are entered in a consecutive list.
Envelopes are opened upon entrance of the patient in the
operating room.
Executing surgeons are briefed on the trial interventions
and permitted surgical techniques. IVC CLAMP is carried
out in an interdisciplinary setting between surgeons and
anaesthetists with the main goal to highly standardise trial
interventions as well as concomitant care according to the
study protocol (e.g. antibiotic prophylaxis, anaesthesia,
etc.).
An independent study nurse is present in the operating
room to monitor and document trial procedures and
Table 6: Laboratory tests performed within the IVC CLAMP Trial.
Parameters Screening Intervention Follow up
Visit 1 (up to 
30 days 
before 
surgery)
Visit 2 (after 
induction of 
anaesthesia 
prior to first 
incision)
Visit 2 
(before 
resection)
Visit 2 (after 
resection, 
before end of 
surgery)
Visit 3 
(POD 1)
Visit 4 + 5 
(POD 3 + 7/
day of 
discharge)
Ventilation Arterial oxygen 
saturation
XXX
Arterial power 
of hydrogen. 
Arterial partial 
pressure of 
oxygen and 
carbon dioxide. 
Base excess.
XXX
Hematology Small blood 
count (from 
whole blood).
XXXXXX
Electrolyte 
metabolism
Sodium, 
potassium, 
calcium 
chloride.*
XXXXXX
Kidney funtion Creatinine, urea 
(from blood 
serum).
XXXXXX
Liver damage/
function
AST, ALT, 
gammaGT, 
Bilirubin (from 
blood serum).
XXXXXX
Coagulation Quick's time, 
INR, Fibrinogen, 
Antithrombin 3.
XXXXXX
Infectious 
parameters
C-reactive 
protein (from 
blood serum).
XX X
*Measures of electrolyte metabolism (sodium, potassium, calcium, chloride) are determied from blood serum at visit 1, 3, 4 and 5. Intraoperatively, 
these measures are determined from arterial blood gas analysis.Trials 2009, 10:94 http://www.trialsjournal.com/content/10/1/94
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events. As blinding of participants in the operating room
is not feasible, assessment of postoperative outcomes is
carried out by a third party blinded to patients' treatment
group as is the patient himself.
Data management and quality assurance
A paper-based case report form (CRF) providing detailed
instructions and definition of outcomes was designed for
documentation within IVC CLAMP. An independent
study nurse not involved in treatment and monitoring of
the patients within the operating room enters all required
data. The data are supposed to be entered as soon as pos-
sible, preferably at the day of a patient's visit and treat-
ment, respectively. Treatments are documented in
separate treatment logs. Standard adverse event forms that
have been validated in previous trials are used for report-
ing of (serious) adverse events.
Ethical and legal considerations
IVC CLAMP is carried out according to the current Decla-
ration of Helsinki (sixth revision, 2008), the principles of
"Good Clinical Practice" (GCP), and the Federal Data Pro-
tection Act.
The clinical trial protocol, patient information and
informed consent sheet have been approved by the inde-
pendent ethics committee of the University of Heidelberg,
Medical School. IVC CLAMP is registered at the Clinical-
Trials.gov protocol registration system http://www.clini
caltrials.gov. The assigned identification number is
NCT00732979.
All patients are instructed on the trial's nature, scope, and
possible consequences by a physician on the day prior to
surgery and patients' written informed consent has to be
obtained for patient enrolment. Participation in IVC
CLAMP is voluntary and patients can withdraw their con-
sent at any time without any negative consequence for
their further treatment.
Patients' personal data are subject to the legal requirement
ensuring confidential medical communication and the
regulations of the Federal Data Protection Act ("Bundes-
datenschutzgesetz"). Patient data are assessed pseudo-
anonymously and transferred and analysed anony-
mously. No person not involved in the trial has access to
patient data.
Discussion
IVC CLAMP represents a RCT to evaluate efficacy and
safety of infrahepatic IVC clamping in comparison to
anaesthesiological methods for CVP reduction in hepatic
resections. CVP reduction carried out by the anaesthesiol-
ogist was introduced in the late 1990's as an effective tech-
nique to reduce blood loss during transection of the liver
parenchyma [6,7]. By restricted intravenous fluid admin-
istration and if required additional application of nitro-
compounds and diuretics CVP can be reliably lowered to
values below 5 mmHg which results in less bleeding from
the hepatic veins. Based on these results CVP reduction
has been widely adopted as part of the perioperative man-
agement of patients undergoing liver resection as indi-
cated by various randomised studies in the field of liver
surgery [13,18,21]. Dehydration might, however, increase
patients' risk for microperfusion deficits with consecutive
organ dysfunction as well as for haemodynamic instabil-
ity and there is still very limited data on safety of patients
undergoing liver resection under the condition of anaes-
thesiological CVP reduction. Against the background of
relevant morbidity associated with hepatic resections
[1,3,22,23], a critical evaluation of currently performed
CVP reduction and alternative techniques to lower CVP
are required.
The present trial compares CVP reduction via infrahepatic
IVC clamping to common anaesthesiological CVP reduc-
tion, which is primarily carried out by restricted intrave-
nous fluid administration and application of diuretics or
nitro-compounds without any type of vascular clamping.
This study design allows assessing efficacy and safety of
infrahepatic IVC clamping as well as a critical evaluation
of anaesthesiological CVP reduction as the current stand-
ard of practice.
In accordance with various previous RCTs in the field of
liver surgery intraoperative blood loss was chosen as pri-
mary endpoint of the present trial. The clinical relevance
of this variable has been demonstrated by several studies
that showed intraoperative blood loss to be an independ-
ent predictor of perioperative outcome and reduction of
intraoperative bleeding is therefore a primary goal for sur-
geons as well as anaesthetists [3,5]. We deliberately chose
entire intraoperative blood loss as opposed to blood loss
during transection of the parenchyma as primary outcome
measure, as we intended to compare the two strategies of
CVP reduction to each other. As fluid restriction starts
right away and thus affects the entire operation prior to
actual liver transection, it may have an impact on patients'
blood loss through the entire duration of the operation.
This trial is designed as a randomised controlled observer
and patient-blinded two-group parallel trial in an attempt
to minimise bias and by this to enable most valid results.
Due to the fact that in the study group undergoing anaes-
thesiological CVP reduction restriction of intravenous
fluid administration has to be started in advance, ran-
domisation in the present trial has to be carried out prior
to abdominal incision. Most patients undergo hepatec-
tomy for malignant disease. Commonly, no resection is
carried out in case exploration of the liver and abdominalTrials 2009, 10:94 http://www.trialsjournal.com/content/10/1/94
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cavity reveals extrahepatic disease, peritoneal dissemina-
tion, and non-resectable hepatic lesions, respectively. To
consider this proportion of patients that actually does not
receive hepatectomy, an additional 30% was added to the
calculated sample size.
The present trial was designed with the intention to mini-
mise bias and by this to generate high-quality data that
help clinicians in their decision-making for the optimal
technique to reduce CVP during hepatectomy. Outcomes
are assessed by an independent study nurse who is not
involved in the design and analysis of the trial. Further-
more, all outcomes have been defined a priori (Table 2).
Besides intraoperative blood loss transfusion of packed
red blood cells is known to adversely affect patients' out-
come [5]. To enable valid comparison of the need for
blood transfusion between patients in both study arms,
standardised transfusion triggers were established.
Within IVC CLAMP transection of the liver parenchyma
by stapler hepatectomy is recommended. However, the
final choice is at discretion of the executing surgeon con-
sidering patients' safety and feasibility of resection. To
limit the number of applied methods, the three most
common techniques (i.e. clamp-crush technique, stapler
hepatectomy, and ultrasonic dissection) are allowed
within the present trial. We are confident that allowance
of three transection techniques does not confound the
results, as currently available evidence does not favour
one technique regarding intraoperative blood loss
[24,25]. Furthermore, this approach increases external
validity of the trial. However, to control for potential bias
the applied transection technique is documented and
considered as a factor in covariance analysis.
In conclusion, the present randomised controlled
observer and patient-blinded two-group parallel trial
compares the technique of infrahepatic IVC clamping to
common anaesthesiological methods for reduction of
CVP during hepatectomy. The results help to assess effi-
cacy and safety of infrahepatic IVC clamping as a routine
technique to lower CVP. Furthermore, they provide a crit-
ical appraisal of the safety of anaesthesiological CVP
reduction and by this a potential strategy to reduce current
morbidity associated with hepatic resection.
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